To see the other types of publications on this topic, follow the link: Alzheimer's.
Journal articles on the topic 'Alzheimer's'
Create a spot-on reference in APA, MLA, Chicago, Harvard, and other styles
Consult the top 50 journal articles for your research on the topic 'Alzheimer's.'
Next to every source in the list of references, there is an 'Add to bibliography' button. Press on it, and we will generate automatically the bibliographic reference to the chosen work in the citation style you need: APA, MLA, Harvard, Chicago, Vancouver, etc.
You can also download the full text of the academic publication as pdf and read online its abstract whenever available in the metadata.
Browse journal articles on a wide variety of disciplines and organise your bibliography correctly.
1
Rajesh, Ravula, Singadi Akhil Reddy, Gandikota Varma Devraj, Raghuram Bhukya, Harika Dasari, and Naaram Srichandana. "Region-based Convolutional Neural Network Driven Alzheimer’s Severity Prediction." International Journal on Recent and Innovation Trends in Computing and Communication 11, no. 6 (August 8, 2023): 465–70. http://dx.doi.org/10.17762/ijritcc.v11i6.7784.
Full textAbstract:
It's important to note that Alzheimer's disease can also affect individuals over the age of 60, and in fact, the risk of developing Alzheimer's increases with age. Additionally, while deep learning approaches have shown promising results in detecting Alzheimer's disease, they are not the only techniques available for diagnosis and treatment. That being said, using Region-based Convolutional Neural Network (RCNN) for efficient feature extraction and classification can be a valuable tool in detecting Alzheimer's disease. This new approach to identifying Alzheimer's disease could lead to a more accurate and personalized diagnosis. It can also help in early treatment and intervention. However, it's still important to continue developing new methods and techniques for this disorder. Considering this our work proposes an innovative Region-based Convolutional Neural Network Driven Alzheimer’s Severity Prediction approach in this paper. The exhaustive experimental result carried out, which proves the efficacy of our Alzheimer prediction system.
2
Corriveau, Roderick A., Walter J. Koroshetz, Jordan T. Gladman, Sophia Jeon, Debra Babcock, David A. Bennett, S. Thomas Carmichael, et al. "Alzheimer's Disease–Related Dementias Summit 2016: National research priorities." Neurology 89, no. 23 (November 8, 2017): 2381–91. http://dx.doi.org/10.1212/wnl.0000000000004717.
Full textAbstract:
Goal 1 of the National Plan to Address Alzheimer’s Disease is to prevent and effectively treat Alzheimer disease and Alzheimer disease–related dementias by 2025. To help inform the research agenda toward achieving this goal, the NIH hosts periodic summits that set and refine relevant research priorities for the subsequent 5 to 10 years. This proceedings article summarizes the 2016 Alzheimer's Disease–Related Dementias Summit, including discussion of scientific progress, challenges, and opportunities in major areas of dementia research, including mixed-etiology dementias, Lewy body dementia, frontotemporal degeneration, vascular contributions to cognitive impairment and dementia, dementia disparities, and dementia nomenclature.
3
VanDongen, Antonius M. "Arc: A new target for treating alzheimer's disease." Open Access Government 43, no. 1 (July 8, 2024): 160–61. http://dx.doi.org/10.56367/oag-043-11454.
Full textAbstract:
Arc: A new target for treating alzheimer's disease Antonius M. VanDongen, Associate Professor from Duke University, walks us through Arc, a new target for treating Alzheimer’s disease. Alois Alzheimer is a German psychiatrist credited with identifying the first case of the debilitating disease named after him. In 1906, he described neurofibrillary tangles and amyloid plaques in his patient’s brain as unique hallmarks of her dementia. Advances in neuroimaging, genetics, and molecular biology have expanded our understanding of the mechanisms underlying Alzheimer’s disease (AD) significantly. But despite heroic efforts to find a cure, there is currently no therapy that prevents, stabilizes or reverses the progression of this disorder that is poised to take on epidemic proportions as the world ages.
4
Gemiralda, Rika Mutiara, Marlaokta Marlaokta, and Marlaokta Marlaokta. "Efek Neuroprotektor Kunyit pada Pasien Alzheimer." Jurnal Ilmu Keperawatan Jiwa 2, no. 3 (November 30, 2019): 171. http://dx.doi.org/10.32584/jikj.v2i3.431.
Full textAbstract:
Alzheimer merupakan penyakit neurogeneratif kronis progresif. Penyakit ini ditandai dengan gangguan fungsi luhur seperti bahasa, kalkulasi, kapasitas belajar dan sulit mengambil keputusan. ‘Pikun’ merupakan istilah yang digunakan masyarakat untuk menggambarkan penyakit ini. Kehilangan memori jangka pendek merupakan kekhasan dari penyakit ini yang menyebabkan penurunkan produktivitas. Alzheimer sering terjadi pada usia > 65 tahun dan juga ditemukan pada sekitar usia 40 tahun. Kunyit (Curcuma longa L.) merupakan tanaman yang berfungsi sebagai neuroprotektor karena dapat menghambat Protein Tau, akivitas asetilkolinesterase dan berfungsi sebagai anti agregasi Aβ dan β secretase inhibitor. Literature review ini bertujuan untuk menjelaskan gambaran efek neuroprotektor pada kunyit terhadap pasien Alzheimer yang sudah dilakukan oleh peneliti sebelumnya. Metode yang digunakan dalam artikel ini adalah penelusuran artikel melalui database NCBI dan Google Scholar. Tahun penerbitan sumber pustaka adalah dari tahun 2001 sampai 2019 dengan 32 sumber pustaka.Tema dalam artikel yang dikumpulkan yaitu terkait gambaran efek neuroprotektor kunyit terhadap pasien Alzheimer. Hasil dari sintesa artikel yang telah ditemukan yaitu kunyit dapat mencegah penurunan kognitif pada pasien Alzheimer. Kata kunci : Alzheimer, Kunyit, Neuroprotektor EFFECT OF NEUROPROTECTOR TURMERIC ON ALZHEIMER’S PATIENTS ABSTRACT Alzheimer's is a chronic progressive neurogenerative disease. This disease is characterized by impaired noble functions such as language, calculations, learning capacity and difficulty making decisions. ‘Pikun’ is a word used by the community to describe this disease. Short-term memory loss is a spesific sign in the patient, this disease causes decrease in productivity. Alzheimer's often occurs at age> 65 years and is also found at around the age of 40 years. Turmeric (Curcuma longa L.) is a plant that functions as a neuroprotector because it can inhibit Tau Proteins, acetylcholinesterase activity and function as anti-aggregation Aβ and β secretase inhibitors. This literature review aims to explain the description of the effects of neuroprotector on turmeric on Alzheimer's patients that have been done by previous researchers. The method used in this article is the search of articles through the NCBI and Google Scholar databases. The themes in the articles collected are related to the description of the effects of turmeric neuroprotector on Alzheimer's patients. The year of publication of library sources is from 2001 to 2019 with 32 library sources. The results of various articles included in this article are turmeric can prevent cognitive decline in Alzheimer's patients. Keywords: Alzheimer's,Turmeric, neuroprotector
5
Zarrouk, Amira, Meryam Debbabi, Maryem Bezine, El Mostafa Karym, Asmaa Badreddine, Olivier Rouaud, Thibault Moreau, et al. "Lipid Biomarkers in Alzheimer's Disease." Current Alzheimer Research 15, no. 4 (February 22, 2018): 303–12. http://dx.doi.org/10.2174/1567205014666170505101426.
Full textAbstract:
Background: There are now significant evidences that lipid metabolism is affected in numerous neurodegenerative diseases including Alzheimer’s disease. These dysfunctions lead to abnormal levels of certain lipids in the brain, cerebrospinal fluid and plasma. It is consequently of interest to establish lipid profiles in neurodegenerative diseases. This approach, which can contribute to identify lipid biomarkers of Alzheimers' disease, can also permit to identify new therapeutic targets. It was therefore of interest to focus on central and peripheral biomarkers in Alzheimer's disease. Methods: A review of the literature on 148 papers was conducted. Based on this literature, the involvement of lipids (cholesterol and oxysterols, fatty acids, phospholipids) in Alzheimer's disease has been proposed. Results: Of the 148 references cited for lipid biomarkers for Alzheimer's disease, 65 refer to cholesterol and oxysterols, 35 to fatty acids and 40 to phospholipids. Among these lipids, some of them such as 24S-hydroxyckolesterol, open up new therapeutic perspectives in gene therapy, in particular. The results on the very long-chain fatty acids suggest the potential of peroxisomal dysfunctions in Alzheimer's disease. As for the phospholipids, they could constitute interesting biomarkers for detecting the disease at the prodromal stage. Conclusion: There are now several lines of evidence that lipids play fundamental roles in the pathogenesis of AD and that some of them have a prognostic and diagnosis value. This may pave the way for the identification of new therapeutic targets, new effective drugs and / or new treatments.
6
Samborska, Julia, Paweł Więckowiak, Karina Stelmaszak, Katarzyna Stencel, Aleksandra Ogiegło-Kowalczyk, Monika Wojtasik, Michał Głodzik, Marek Miśkiewicz, Katarzyna Żak, and Martyna Łęcka. "The impact of the ketogenic diet on the health of patients with Alzheimer’s disease." Journal of Education, Health and Sport 52 (January 11, 2024): 98–110. http://dx.doi.org/10.12775/jehs.2024.52.007.
Full textAbstract:
INTRODUCTION:
Diet is an integral element of every individual's health. Its impact on the functioning of the human body has fascinated scientists for years. One of the diets that alters the mechanism of the body's functioning is the ketogenic diet. The impact of the ketogenic diet on various disorders is still under investigation. It is known to have shown numerous benefits in reducing epileptic seizures, but its impact on other neurological disorders is less known. In this literature review, the efficacy of ketogenic therapies was assessed in Alzheimer's disease.
AIM OF STUDY:
Review of the current literature (since 2018) on the effects of implementing a ketogenic diet in patients with Alzheimer's disease.
MATERIALS AND METHODS:
The review was based on data gathered from the PubMed database using the keywords: 'ketogenic diet in Alzheimer’s disease,' 'ketogenic therapies Alzheimer disease,' and 'ketogenic diet in neurological disease’.
SUMMARY:
The ketogenic diet enhances the daily functioning of Alzheimer's patients. It significantly improves their cognitive functions, and changes in brain blood flow are visible in imaging studies. The ketogenic diet also positively modulates the gut microbiome in Alzheimer's patients. It represents a promising option in combating cognitive symptoms of Alzheimer's disease.
7
Ruzny, Fathima Aamina, Muhammed Ifham Mohamed Imtiyas, and Abdul Raheem Rizvie. "Challenges to Alzheimer Care in Pakistan." Journal of the Pakistan Medical Association 74, no. 6 (May 24, 2024): 1214. http://dx.doi.org/10.47391/jpma.10703.
Full textAbstract:
Madam, Alzheimer's, the prime culprit behind Dementia, is a neurodegenerative disorder that gradually erases memory and cognition, affecting daily tasks 1. Symptoms often emerge in later years, and in Pakistan, where a rising aging population and middle-income status prevail, the risk amplifies. By 2030, global dementia cases can soar to 1.3 million from 850,000 in 2015, surging to 3.6 million by 2050 without preventive action 2. Urgent attention beckons. Yet, challenges abound. With Pakistan’s depleting literacy rate currently of 58.9% in 2023, misconceptions are likely 3. Stigma, cultural norms, and language barriers shroud the path to treatment. Moreover, mental health issues like depression, an Alzheimer’s symptom, are seen as taboo, deterring help-seeking. Till date, the lack of national databases stifles research progress, and a shortage of neurologists-just less than 150 for millions of people-worsens with scarce training programs4. Private caretakers in this developing country may be limited. As this chronic Alzheimer's has no cure, high drug costs hinder adherence, while the affordability of the new "Leqembi" drug, if approved, raises concerns. Additionally, access to MRI and CT scanning equipment in Pakistan is not widespread and their procurement along with testing entail significant costs. Furthermore, government policies and funding for Alzheimer's treatment and research might be insufficient with the rising aging population. NGOs in Pakistan related to Alzheimers are very limited- “Alzheimers Pakistan” the one and only centered in just three regions across this vast country. Solutions for these challenges emerge as vibrant threads. How can we aid patients and families in Alzheimer education? Imagine engaging workshops and media partnerships with prominent figures like the UNICEF Goodwill ambassadors thereby igniting a good community-healthcare bond, and envision ‘Alzheimer homes’ for patients lacking caregivers. Besides, a national database involving stakeholders, from NGOs to healthcare providers, can not only pave the way for easy data accessibility but also to proper treatment plans and protocols. Engaging these stakeholders could also lead to initiatives for more affordable medicines. For the shortage of neurologists, medical tourism initiatives that attract foreign neurologists to work temporarily in the country, sharing their expertise and contributing to healthcare delivery can be deployed. Targeted training for healthcare professionals and collaborating with international organizations for increased research, clinical trial participation and even in machinery purchase hold a promise to resolving this issue. Conclusively, emphasizing these concerns holds utmost significance in the pursuit of discovering effective interventions for this incurable ailment.
8
Sianturi, Aditya Gloria Monalisa. "Stadium, Diagnosis, dan Tatalaksana Penyakit Alzheimer." Majalah Kesehatan Indonesia 2, no. 2 (October 25, 2021): 39–44. http://dx.doi.org/10.47679/makein.202132.
Full textAbstract:
Dementia is a general term for loss of memory that can occur along with behavioral or psychological symptoms in patients. The first cause of dementia patients is Alzheimer's disease. Alzheimer’s disease is a brain degenerative disease and the most common cause of dementia. In Alzheimer’s disease, there are three development stages, which is stage 1, stage 2, and stage 3 with different clinical symptoms at each stage. There are several clinical criteria for establishing a definitive diagnosis of Alzheimer’s disease and also support examinations have to be carried out. Until now, Alzheimer’s treatment has not been cured. Giving some pharmacotherapy only to reduce the progression of Alzheimer’s disease. Demensia merupakan hilangnya ingatan yang bisa timbul bersama dengan gejala gangguan perilaku maupun psikologis pada seseorang. Penyebab pertama penderita demensia adalah penyakit Alzheimer. Penyakit Alzheimer adalah penyakit degeneratif otak dan penyebab paling umum dari demensia. Pada penyakit Alzheimer terdapat beberapa stadium perkembangan penyakit Alzheimer yaitu stadium 1, stadium 2, dan stadium 3 dengan gejala klinik yang berbeda di setiap stadium. Terdapat beberapa kriteria klinis dalam penegakan diagnosis definitif penyakit Alzheimer serta harus dilakukan pemeriksaan penunjang. Pada tatalaksana penyakit Alzheimer hingga saat ini memang belum dapat disembuhkan, Pemberian obat-obatan hanya untuk mengurangi progresifitas penyakit Alzheimer.
9
Marintan, Elita, Brian Wasita, and Adi Magna. "EFFECT OF DATE FRUIT (PHOENIX DACTYLIFERA L.) EXTRACT ON TNFα LEVELS AND BRAIN WEIGHT OF ALZHEIMER’S MODEL RATS." MNJ (Malang Neurology Journal) 8, no. 1 (January 1, 2022): 25–29. http://dx.doi.org/10.21776/ub.mnj.2022.008.01.6.
Full textAbstract:
Background: Alzheimer's disease (AD) is a neurodegenerative disorder marked by brain inflammation resulted in structural damage and brain dysfunction. Tumor necrosis factor α (TNFα) is a cytokine that plays an important role in inflammation. Dates fruit may help to fight oxidative stress and inflammation in the brain. Objective: To determine the effect of date fruit extracts on blood TNFα levels and brain weight of alzheimer’s model rats. Methods: This research is a laboratory experimental study by post-test only with control group design using alzheimer model rats. This study used 6 treatment groups with simple randomization. Each treatment group was represented by 8 Sprague Dawley rats. The normal control group (KN) was not induced by Hcy and was not given date palm extract, the negative control group (K-) was the Alzheimer's experimental rats which was not given the date palm extract, the positive group was the Alzheimer's experimental rats which was given the Donepezil (K+). Groups P1, P2, P3 were Alzheimer's experimental rats that were given date palm extract at a dose of 200, 400,800 mg / kgBW / day. The effect of date palm extract dosage on TNFα levels and brain weight were analyzed using the One Way Anova test followed by Tukey's post hoc test. Results: The difference in TNFα levels between groups showed a significant difference (p = 0.00). Meanwhile there was no significant difference in brain weight among all groups (p > 0,05). Conclusion: Date palm extract at doses of 200, 400, 800 mg / kgBW can decrease blood TNFα levels of Alzheimer’s model rats.
10
Alamri, Khairun N. H., Jimmy Posangi, and Edward Nangoy. "Perbandingan Efektivitas Penggunaan Donepezil dan Memantine Terhadap Perbaikan Fungsi Kognitif pada Penyakit Alzheimer." JURNAL BIOMEDIK (JBM) 13, no. 2 (March 29, 2021): 218. http://dx.doi.org/10.35790/jbm.13.2.2021.31950.
Full textAbstract:
Abstract: Pharmacological therapy for Alzheimer’s disease are cholinesterase inhibitors (donepezil) and N-methyl-D-aspartate (memantine) receptor antagonists. The use of donepezil and memantine in elderly patients must be considered because they can affect the pharmacokinetic process of drugs and the effect of drugs on the body.The aim of the study was knowing the difference in the effectiveness of using Donepezil and Memantine on the improvement of cognitive function in Alzheimer's patients. This study was in the form of a literature review with data searches using three databases, namely Pubmed, ClinicalKey, Science Direct. Keywords used are Donepezil AND Cognitive .AND Alzheimer, Memantine AND Cognitive AND Alzheimer. After being selected, 12 literature was obtained based on inclusion and exclusion criteria. In this study, Donepezil and memantine are beneficial in improving cognitive function in moderate to severe Alzheimer's disease but side effects tend to be more frequent with the use of donepezil than memantine. donepezil and memantine can be combined for the treatment of Alzheimer's disease but must pay attention to the effectiveness in clinical evaluation of patients and the cost effectiveness of the combination. Conclusion: Memantine and donepezil are effective and safe to use as therapy for moderate to severe Alzheimer’s disease. Donepezil and memantine combination therapy is more effective than donepezil or memantine monotherapy.Keywords: Donepezil, Memantine, Cognitive, Alzheimer Abstrak: Terapi farmakologi untuk penyakit alzheimer adalah inhibitor kolinesterase (donepezil) dan antagonis reseptor N-metil-D-aspartat (memantine). Penggunaan donepezil dan memantine pada pasien lanjut usia harus diperhatikan karena dapat mempengaruhi proses farmakokinetik obat dan efek obat terhadap tubuh. Penelitian ini bertujuan untuk mengetahui perbedaan efektivitas penggunaan Donepezil dan Memantine terhadap peningkatan fungsi kognitif pada pasien Alzheimer. Penelitian ini berbentuk Literature Review dengan pencarian data menggunakan tiga database yaitu Pubmed, ClinicalKey, Science Direct. Kata kunci yang digunakan adalah Donepezil AND Cognitive AND Alzheimer, Memantine AND Cognitive AND Alzheimer. Setelah dipilih, diperoleh 12 literatur berdasarkan kriteria inklusi dan eksklusi. Dalam penelitian ini, Donepezil dan memantine bermanfaat dalam meningkatkan fungsi kognitif pada penyakit Alzheimer sedang hingga berat tetapi efek sampingnya cenderung lebih sering dengan penggunaan donepezil daripada memantine. donepezil dan memantine dapat digabungkan untuk pengobatan penyakit Alzheimer tetapi harus memperhatikan keefektifan dalam evaluasi klinis pasien dan efektivitas biaya dari kombinasi tersebut. Kesimpulan: Memantine dan donepezil efektif dan aman digunakan sebagai terapi penyakit Alzheimer sedang hingga berat. Terapi kombinasi donepezil dan memantine lebih efektif dibandingkan dengan monoterapi donepezil atau memantine.Kata Kunci : Donepezil, Memantine, Cognitive, Alzheimer
11
Aizah, Havina Nurul, Amel Yanis, Hirowati Ali, Tofrizal Tofrizal, Cimi Ilmiawati, and Dessy Arisanty. "Pengaruh Pemberian Mesenchymal Stem Cells Wharton's Jelly terhadap Ekspresi Gen Sirtuin 1 pada Tikus Model Alzheimer." Jurnal Kesehatan Andalas 12, no. 1 (July 22, 2023): 9. http://dx.doi.org/10.25077/jka.v12i1.2140.
Full textAbstract:
Mesenchymal Stem Cells Wharton's Jelly (MSC-WJ) has become a new hope for Alzheimer's disease due to its capability to suppress Amyloid-beta (Aβ) plaques formation. It is found that people with Alzheimer's disease have a lower expression of Sirtuin-1 because of the oxidative stress that was produced by Aβ plaques. Objective: To observe the Sirtuin-1 gene in Alzheimer's disease rat models that AlCl3 was inducing after being given MSC-WJ. Methods: This was an experimental study with a post-test-only control group design, including three groups with a total sample of 18 samples of Alzheimer RNA rat models. Group-1without AlCl3 and MSC-WJ; Group-2 with AlCl3; Group-3 AlCl3 and MSC-WJ. Mean value of the Sirtuin-1 gene was obtained by the Image-J application using a semiquantitative method which was then tested using the One Way ANOVA test. The study was significant if the p-value < 0,05. Results: This study found that the mean ± standard error value of the Sirtuin-1 gene in three groups were 0.18±0.04; 0.16±0.03; and 0.36±0.06 respectively. The statistical test showed a significant difference between the three groups (p = 0.014). Conclusion: There was an increased Sirtuin 1 gene expression in Alzheimer’s rat Model after being given Mesenchymal Stem Cells Wharton’s Jelly.Keywords: Alzheimer, MSC-WJ, Sirtuin-1
12
Conte, G. L., and M. Pomponi. "Alzheimer's or alzheimer-perusini's disease?" European Psychiatry 22 (March 2007): S297. http://dx.doi.org/10.1016/j.eurpsy.2007.01.1008.
Full text
13
Graham, Nori. "Alzheimer's Disease International." International Psychogeriatrics 9, no. 1 (March 1997): 5–6. http://dx.doi.org/10.1017/s1041610297004146.
Full textAbstract:
Alzheimer's Disease International (ADI) aims to promote and support the work of national Alzheimer associations. Their main purpose is to support carers of people with Alzheimer's disease and related dementias, and to raise awareness of the impact of the disease on the individual and the carer.
14
Appel, Jason, Elizabeth Potter, Qian Shen, Gustavo Pantol, Maria T. Greig, David Loewenstein, and Ranjan Duara. "A Comparative Analysis of Structural Brain MRI in the Diagnosis of Alzheimer’s Disease." Behavioural Neurology 21, no. 1-2 (2009): 13–19. http://dx.doi.org/10.1155/2009/103123.
Full textAbstract:
Dementia is a debilitating and life-altering disease which leads to both memory impairment and decline of normal executive functioning. While causes of dementia are numerous and varied, the leading cause among patients 60 years and older is Alzheimer’s disease. The gold standard for Alzheimer’s diagnosis remains histological identification of amyloid plaques and neurofibrillary tangles within the medial temporal lobe, more specifically the entorhinal cortex and hippocampus. Although no definitive cure for Alzheimer's disease currently exists, there are treatments targeted at preserving cognition and memory while delaying continued loss of function. Alzheimer's disease exists along a spectrum of cognitive decline and is often preceded by Mild Cognitive Impairment (MCI). Patients with MCI demonstrate memory loss and cognitive impairment while still continuing normal activities of daily living, and are considered to be at increased risk for developing Alzheimer's Dementia. Identifying patients with prodromal states of Alzheimer's dementia such as MCI may allow initiation of appropriate treatment planning and delay of cognitive decline. Therefore, the need for a non-invasive early biomarker for the detection of Alzheimer's disease has never been greater. Multiple neuroimaging methods utilizing visual rating scales, volumetric measurements, and automated methods have been developed to identify, quantify, and track anatomic sequelae of Alzheimer’s Disease.
15
Rosikin and Riri Narasati. "Penerapan Metode Convolutional Neural Network untuk Diagnosa Penyakit Alzheimer." Kopertip : Jurnal Ilmiah Manajemen Informatika dan Komputer 7, no. 2 (June 30, 2023): 48–53. http://dx.doi.org/10.32485/kopertip.v7i2.347.
Full textAbstract:
Abstract— Alzheimer's disease is a neurodegenerative disease that develops gradually, and is associated with cardiovascular and cerebrovascular problems. Alzheimer's is a serious disease that can cause a decline in cognitive function, memory loss, and behavioral disorders, significantly impacting the patient's quality of life and requiring long-term care. One way to detect Alzheimer's disease is by using Magnetic Resonance Imaging (MRI) images. However, the process of detecting Alzheimer's disease using MRI images requires manual interpretation which is time-consuming, expensive and difficult for all doctors to do. The use of Convolutional Neural Network (CNN) can help in detecting Alzheimer's through MRI images. In this research, CNN method is used to detect Alzheimer's disease. Then the model that has been trained will be applied to a simple website. The results of this study managed to achieve a very high level of accuracy, which is 99%. With an average recall value of 99% and precision of 99%. In addition, the model in this research is able to provide consistent and stable results. This research shows that the use of Convolutional Neural Network (CNN) method is very effective in detecting Alzheimer's disease in MRI images. This research aims to create a system that can detect Alzheimer's accurately and efficiently, enable early detection, and assist medical personnel in rapid and accurate diagnosis. It is hoped that this research can make a positive contribution to the detection and treatment of Alzheimer's through the utilization of deep learning methods and computer vision technology.
Keywords: Alzheimer's, Convolutional Neural Network (CNN), Magnetic Resonance Imaging (MRI), Disease detection, Deeplearning
Abstrak— Penyakit Alzheimer adalah penyakit neurodegeneratif yang berkembang secara bertahap, serta memiliki keterkaitan dengan masalah kardiovaskular dan serebrovaskular. Alzheimer merupakan penyakit serius yang dapat menyebabkan penurunan fungsi kognitif, kehilangan ingatan, dan gangguan perilaku, berdampak signifikan pada kualitas hidup pasien serta memerlukan perawatan jangka panjang. Salah satu cara untuk mendeteksi penyakit Alzheimer adalah dengan menggunakan Citra Magnetic Resonance Imaging (MRI). Namun, proses deteksi penyakit Alzheimer menggunakan citra MRI memerlukan interpretasi manual yang memakan waktu, mahal dan sulit dilakukan semua dokter. Penggunaan Convolutional Neural Network (CNN) dapat membantu dalam mendeteksi Alzheimer melalui citra MRI. Pada penelitian ini digunakan metode CNN untuk mendeteksi penyakit Alzheimer. Kemudian model yang telah dilatih akan diterapkan ke dalam sebuah website sederhana. Hasil dari penelitian ini berhasil mencapai tingkat accuracy yang sangat tinggi, yaitu sebesar 99%. Dengan nilai rata-rata recall sebesar 99% dan precision sebesar 99%. Selain itu, model pada penilitian ini mampu memberikan hasil yang konsisten dan stabil. Penelitian ini menunjukan bahwa penggunaan metode Convolutional Neural Network (CNN) sangat efektif dalam mendeteksi penyakit Alzheimer pada citra MRI. Penelitian ini bertujuan untuk menciptakan sistem yang dapat mendeteksi Alzheimer secara akurat dan efisien, memungkinkan deteksi dini, serta membantu tenaga medis dalam diagnosis cepat dan akurat. Diharapkan penelitian ini dapat memberikan kontribusi positif dalam deteksi dan penanganan Alzheimer melalui pemanfaatan metode deep learning dan teknologi computer vision.
Kata Kunci: Alzheimer, Convolutional Neural Network (CNN), Magnetic Resonance Imaging (MRI), Deteksi penyakit, Deeplearning
16
Suryoadji, Kemal Akbar, Muhammad Faruqi, and Vincentius Juan Aryaputra. "Underweight Nutritional Status as a Predictor of Mortality in Alzheimer's Disease : A Systematic Review and Meta-Analysis of Prospective Cohort Study." Cermin Dunia Kedokteran 49, no. 6 (May 25, 2022): 338. http://dx.doi.org/10.55175/cdk.v49i6.1884.
Full textAbstract:
<p>Purpose: The research was conducted to determine the risk of mortality in underweight Alzheimer's disease patients and to consider nutritional maintenance as an important management approach in Alzheimer’s patients. Methods: This review used publications found in Pubmed, Scopus, Cochrane, and ScienceDirect. The keywords were “((Alzheimer's Diseased) AND (Underweight) AND (Mortality))”. Meta-analysis review with Revman 5 software calculated the average relative risk from all selected cohort studies. Result: The process identify 230 articles, only three studies with 1423 patients were included. The meta-analysis result showed that based on their BMI status, underweight patients have a higher risk of mortality than normal weight patients. (RR: 1.65, 95% CI: 1.32-2.06). Conclusion: Underweight nutritional status in Alzheimer's patients increases the risk of mortality compared to the individuals with normal nutritional status.</p><p>Tujuan: Penelitian ini dilakukan untuk menentukan risiko kematian pasien penyakit Alzheimer yang memiliki berat badan kurang dan mempertimbangkan pemeliharaan nutrisi sebagai bagian dari pendekatan tata laksana pasien Alzheimer. Metode: Tinjauan dalam publikasi ini diambil dari Pubmed, Scopus, Cochrane, dan ScienceDirect. Kata kunci yang digunakan ialah “((Alzheimer Diseased) AND (Underweight) AND (Mortality))”. Tinjauan meta-analisis menggunakan perangkat lunak Revman 5 menghitung rata-rata risiko relatif dari semua studi kohort yang dipilih. Hasil: Dari 230 artikel yang berhasil diidentifikasi, 3 studi dengan 1423 pasien dimasukkan dalam studi. Hasil meta-analisis menunjukkan berdasarkan status Indeks Massa Tubuh, bahwa pasien dengan berat badan kurang memiliki risiko mortalitas lebih tinggi daripada pasien dengan berat badan normal (RR: 1.65, 95% CI: 1.32-2.06). Simpulan: Kondisi nutrisi dengan berat badan kurang pada pasien Alzheimer meningkatkan risiko mortalitas dibandingkan dengan individu yang memiliki berat badan normal.</p>
17
Förstl, Hans, Alistair Burns, Phil Luthert, Nigel Cairns, and Raymond Levy. "The Lewy-Body Variant of Alzheimer's Disease." British Journal of Psychiatry 162, no. 3 (March 1993): 385–92. http://dx.doi.org/10.1192/bjp.162.3.385.
Full textAbstract:
At post-mortem, Lewy bodies (LBs) were found in the brainstem and neocortex of eight out of 65 patients who had been collected during a prospective long-term study on clinically diagnosed Alzheimer’s disease. All eight patients had accompanying Alzheimer pathology which was less severe than in a sample of eight age and sex-matched patients from the same study with neuropathologically verified Alzheimer's disease. Parkinsonian features were more common in patients with LBs. There were no particular differences in duration of illness, severity of cognitive impairment, presence of hallucinations, or fluctuations in the course of illness. Frontal cerebral atrophy was more marked in patients with LBs, as was the loss of neurons in the basal nucleus of Meynert and the substantia nigra. Cognitive performance correlated with the number of pigmented neurons in the substantia nigra. We conclude that the differential diagnosis of LB dementia should be considered in patients satisfying NINCDS-ADRDA criteria for Alzheimer-type dementia who show marked Parkinsonian features and a frontal accentuation of cerebral atrophy.
18
Ojetunde, Ayodeji Oluwatobi. "The Neuroprotective and Therapeutic Effects of Medicinal Plants and Natural Products against Aluminium Chloride-Induced Alzheimer’s Disease: Recent Update." Biology, Medicine, & Natural Product Chemistry 13, no. 1 (May 2, 2024): 7–33. http://dx.doi.org/10.14421/biomedich.2024.131.7-33.
Full textAbstract:
Alzheimer's disease currently affects more than 35 million individuals worldwide. Aluminium has been implicated in the pathogenesis of various cognitive disorders. Meanwhile, aluminium chloride (AlCl3) has a significant impact on the progression of neurodegenerative diseases including Alzheimer's disease. The majority of Alzheimer's disease medications now on the market are cholinesterase inhibitors. However, the effectiveness of these drugs is limited because they can't totally arrest the progression of the disease. The utilization of medicinal plants and natural products may present excellent prospective options for Alzheimer's disease prevention and therapy. This study summarized medicinal plants and natural products for the prevention and treatment of AlCl3-induced Alzheimer’s disease as an alternative therapy using published data in the literature from the years 2021-2023. The medicinal plants and natural products help to reduce Alzheimer’s disease pathogenesis by controlling different pathways and could be used as a therapeutic agent against the symptoms. The majority of the medicinal plants and natural products discussed in this review have been shown to have neuroprotective, antioxidant, anti-amyloid, anti-inflammatory, anticholinesterase, anti-apoptotic, and therapeutic actions. Therefore, medicinal plants and natural products may offer neuroprotective and therapeutic effects in the treatment of Alzheimer’s disease.
19
Malabadi, Ravindra B., Kiran P. Kolkar, Neelambika T. Meti, and Raju K. Chalannavar. "Recent updates on the role of herbal medicine for Alzheimer's disease (Dementia)." International Journal of Current Research in Biosciences and Plant Biology 8, no. 1 (January 6, 2021): 14–45. http://dx.doi.org/10.20546/ijcrbp.2021.801.002.
Full textAbstract:
This review paper highlights the use of medicinal plants in the management of Alzheimer's disease and memory deficit. Alzheimer’s disease is the most common form of dementia, a serious brain disorder that impacts daily living through memory loss and cognitive changes. Alzheimer's disease is also age-related neurodegenerative disorders caused by progressive loss of structure or function of neurons, resulting in neuronal cell death. Alzheimer's patients have an acetylcholine deficiency. Stressful conditions, free radicle scavanging and oxidation are often associated with loss of memory and cognitive functions, which may lead to threats of schizophrenia and Alzheimer's disease. However, the use of allopathic drugs has resulted in the adverse side effects on the human body and thus limits the use of such drugs. Herbal cognitive enhancer drugs have shown their potent effect in Alzheimer’s disease due to their antioxidant and neuropharmacological actions. The use of natural cognitive enhancers evidenced to improve mental functions such as cognition, memory, intelligence, motivation, attention and concentration. Traditional Ayurvedic herbal system of medicine is fundamentally preventive, protective, nutritive, curative and less expensive. Therefore, the use of herbal medicine for the treatment of Alzheimer's disease is a novel approach without any side effects.
20
Dias, Mariana, and Valmir Moratelli. "A condução narrativa na subjetividade de um personagem com Alzheimer: encruzilhada de incertezas no roteiro do filme Meu Pai." Cambiassu: Estudos em Comunicação 16, no. 28 (December 28, 2021): 288. http://dx.doi.org/10.18764/2176-5111v16n28.2021.29.
Full textAbstract:
O artigo tem como objetivo explorar possibilidades narrativas de um narrador-personagem com a Doença de Alzheimer. Tendo como objeto o filme Meu Pai (The Father, 2020), discute-se as escolhas textuais e imagéticas para a imersão do espectador na dualidade das cenas, além das fragilidades inseridas nos processos mnemônicos do protagonista. Como metodologia, descreve-se o emaranhado narrativo, a partir da definição biomédica da doença, conhecida por atingir a memória do sujeito. Como aspectos conclusivos, aponta-se como a obra audiovisual contribui para compreensão de consequências sociais do Alzheimer, possibilitando criar empatia a respeito desta doença ainda sem cura definitiva.The narrative diretion in the subjectivity of a character with Alzheimer’s: crossroads of uncertainties in the script for the film The FatherAbstractThe article aims to explore narratives of a narrator-character with Alzheimer's Disease. With the object of the film The Father (2020), the textual and imagery choices for the immersion of the spectator in the duality of the scenes are discussed, in addition to the weaknesses inserted in the protagonist's mnemonic processes. As a methodology, we teach the narrative entanglement, from the biomedical definition of the disease, known for reaching the subject's memory. As the conclusive aspects, it is pointed out how an audiovisual work contributes to the understanding of the social consequences of Alzheimer's, making it possible to create empathy about this disease that still has no definitive cure.Keywords: Memory; old age; alzheimer’s.
21
Shahzadi, Maria, Bareera Saeed, Muhammad Azzam Khan, Amna Rashid, Muhammad Bilal, Roma Imtiaz, and Tallat Anwar Faridi. "A Review on the Techniques for Early Diagnosis of Alzheimer’s Disease." Lahore Garrison University Journal of Life Sciences 6, no. 03 (September 15, 2022): 268–81. http://dx.doi.org/10.54692/lgujls.2022.0603228.
Full textAbstract:
Alzheimer’s disease is a neurological condition in which there is rapid deterioration of the brain and it affects around 50 million people globally. The most obvious sign of Alzheimer’s is dementia which is primarily an affliction of old age. Majority of the people presenting with dementia in old age are Alzheimer’s patients. The symptoms of Alzheimer’s disease are debilitating and have the ability to utterly disrupt a person's normal life. It is only discovered after this terrible disease has destroyed all neurons, thus there is little chance to cure it or reverse the adverse effects. There are two types of techniques for detecting Alzheimer's disease: invasive and non-invasive techniques. Invasive method obtains data from the patient bydrawing a small amount of blood or performing a lumbar puncture, whereas noninvasive method collects data using imaging techniques like MRI and CT scan. Invasive technique, on the other hand, is thought to be a more accurate indicator of Alzheimer's disease than non-invasive technique since it provides strong biomarkers. Once Alzheimer's disease has progressed to its final stage, it is incurable. Treatment is only viable when the disease is in its initial stages. Future treatments for Alzheimer's disease will focus on the causative maladies of neurofibrillary tangles (ptau) and senile plaques (A). The pathological traits connected to debilitating disease, special protein, b proteins, are critical for future therapeutics
22
Cummings, Jeffrey L. "Update on Alzheimer's Disease: One Hundred Years After Dr. Alois Alzheimer." CNS Spectrums 13, S2 (February 2008): 4–6. http://dx.doi.org/10.1017/s1092852900002819.
Full textAbstract:
Alzheimer's disease was first described by Alois Alzheimer in 1906, and first appeared in the medical literature in 1907. The medical community has been ruminating about Alzheimer's disease for over 100 years, and only recently have Alzheimer's disease therapies begun to emerge. However, many vital questions remain, pertinent not only to physicians but to the public at large. For example, how likely is it that a particular individual will develop Alzheimer's disease? What can one do to avoid getting Alzheimer's disease? What are the current and promising treatments for Alzheimer's disease? While there are grey areas, the Alzheimer's disease field is beginning to find solid answers to these questions. There are risk factors that individuals can control, and emerging treatments are cause for optimism.
23
Ahmed, Amira S., Rehab M. Elgharabawy, and Amal H. AL-Najjar. "Ameliorating effect of anti-Alzheimer’s drugs on the bidirectional association between type 2 diabetes mellitus and Alzheimer’s disease." Experimental Biology and Medicine 242, no. 13 (May 23, 2017): 1335–44. http://dx.doi.org/10.1177/1535370217711440.
Full textAbstract:
Mild to severe forms of nervous system damage were exhibited by approximately 60–70% of diabetics. It is important to understand the association between type 2 diabetes mellitus and Alzheimer’s disease. The aim of the present work is to understand the bidirectional association between type 2 diabetes and Alzheimer’s disease pathogenesis, that was monitored by glycaemic status, lipid profile, amyloid beta 40 and 42 (Aβ40 and Aβ42), C-reactive protein, total creatine kinase, total lactate dehydrogenase, D-dimer and magnesium measurements, to assess the association between theses biochemical markers and each other, to estimate the possibility of utilizing the amyloid beta as biochemical marker of T2D in Alzheimer's patients, and to evaluate the effect of piracetam and memantine drugs on diabetes mellitus. This study involved 120 subjects divided into 20 healthy control (group I), 20 diabetic patients (group II), 20 Alzheimer’s patients (group III), 20 diabetic Alzheimer's patients with symptomatic treatment (group IV), 20 diabetic Alzheimer's patients treated with memantine (group V), and 20 diabetic Alzheimer's patients treated with piracetam (group VI). The demographic characteristics, diabetic index, and lipid profile were monitored. Plasma amyloid beta 40 and amyloid beta 42, C-reactive protein, total creatine kinase, total lactate dehydrogenase, D-dimer, and magnesium were assayed. The levels of amyloid beta 40 and amyloid beta 42 were significantly elevated in diabetic Alzheimer's patients with symptomatic treatment (group IV) compared to group II (by 50.5 and 7.5 fold, respectively) and group III (by 25.4 and 2.8 fold, respectively). In groups II, III, IV, V and VI, significant and positive associations were monitored between insulin and amyloid beta 40, amyloid beta 42, C-reactive protein, total creatine kinase, and D-dimer. Diabetic markers were significantly decreased in diabetic Alzheimer’s patients treated with anti-Alzheimer’s drugs (especially piracetam) compared to group IV. This study reveals the role of amyloid beta 40, amyloid beta 42, insulin, HbA1c, lipid profile disturbance, C-reactive protein, D-dimer, and magnesium in the bidirectional correlation between T2D and pathogenesis of Alzheimer’s disease, that is powered by their correlations, and therefore the possibility of utilizing Aβ as a biochemical marker of T2D in Alzheimer's patients is recommended. Impact statement Several aspects associated with T2D that contribute to AD and vice versa were investigated in this study. Additionally, this work reveals the role of Aβ40, Aβ42, insulin, HbA1c, lipid profile disturbance, CRP, D-dimer, and magnesium in the bidirectional association between T2D and the pathogenesis of AD, that is powered by their correlations, and therefore the possibility of utilizing Aβ as a biochemical marker of T2D in Alzheimer's patients is recommended. Furthermore, the ameloriating effect of anti-Alzheimer’s drugs on diabetes mellitus confirms this association. Hereafter, a new approach for treating insulin resistance and diabetes may be developed by new therapeutic potentials such as neutralization of Aβ by anti-Aβ antibodies.
24
Rimmer, Elizabeth. "Alzheimer's Disease International." International Psychiatry 3, no. 4 (October 2006): 22–23. http://dx.doi.org/10.1192/s1749367600004999.
Full textAbstract:
Alzheimer's Disease International (ADI) is the international federation of 75 Alzheimer associations throughout the world and is in official relations with the World Health Organization. ADI was established to raise awareness about dementia, strengthen Alzheimer associations and provide a platform for the exchange of knowledge with the ultimate goal of improving the quality of life of people with dementia and their families.
25
Tagarelli, Antonio, and Anna Piro. "Alois Alzheimer: a hundred years after the discovery of the eponymous disorder." International Journal of Biomedical Science 2, no. 2 (September 15, 2006): 196–204. http://dx.doi.org/10.59566/ijbs.2006.2196.
Full textAbstract:
The familiar term "Alzheimer's disease" was coined by Emil Kraepelin to honour his pupil, Alois Alzheimer. However, little is known about the life of the man after whom this important and well-known disease was termed. On the centennial of the discovery of Alzheimer's disease, it is appropriate to report some aspects of the life and scientific work of Alois Alzheimer. The authors contacted all the libraries of the Universities where Alzheimer studied and/or worked to receive any original material regarding Alois Alzheimer. This review is based for a most part on an original biography written by Konrad and Urlike Maurer after the interviews to Alzheimer's nieces, Hildegard Koeppen, Ilse Lieblein, Barbel Lippert, Karin Weiβ, and his nephew, Rupert Finsterwalder. The authors obtained this biography from the Central Library of Medicine in Koeln.
26
TEKİN, Esra, Ayşegül KÜÇÜK, and Sibel CANBAZ KABAY. "Evaluation of Early Diagnosis via Some Blood Parameters in Alzheimer Type Dementia and Type 2 Diabetes Mellitus Patients." Turkish Journal of Diabetes and Obesity 7, no. 3 (December 31, 2023): 206–13. http://dx.doi.org/10.25048/tudod.1370520.
Full textAbstract:
Aim: Alzheimer's disease is a neurodegenerative disease with cognitive loss, which does not have a curative treatment and a bloodbased
biomarker to make a definitive diagnosis. There is a strong relationship between Alzheimer's disease and type 2 diabetes mellitus.
Neutrophil-lymphocyte, platelet-lymphocyte and monocyte-lymphocyte ratios are recommended parameters as inflammation markers.
It was aimed to compare blood parameters and their ratios to each other in terms of their potential to provide early diagnosis in patients
with Alzheimer's disease and type 2 diabetes mellitus.
Material and Methods: 80 healthy controls, 47 type 2 diabetes mellitus and 45 Alzheimer's type dementia patients were included in this
study. Various blood parameters and their ratios to each other were scanned. One way ANOVA and post hoc Scheffe tests were used for
statistical analysis.
Results: Serum iron levels were lower in type 2 diabetes mellitus (53.21±29.28 μg/dL) and Alzheimer’s disease (61.26±21.69 μg/dL)
groups compared to the control (76.96±30.99 μg/dL) (p=0.001). Lymphocyte numbers were lower in type 2 diabetes mellitus (1.94±0.79
count.10³) and Alzheimer’s disease (1.84±0.68 count.10³) groups compared to the control (2.25±1.03 count.10³) (p=0.032). Monocytelymphocyte
ratio were significantly higher in type 2 diabetes mellitus (0.3±0.18) and Alzheimer’s disease (0.28±0.11) groups compared
to the control (0.24±0.1) (p=0.039).
Conclusion: The high monocyte-lymphocyte ratio can be considered as an indicator of systemic inflammation in Alzheimer's disease
and type 2 diabetes mellitus. In conclusion, serum iron levels, lymphocyte numbers and monocyte-lymphocyte ratio as inflammation
markers can be useful for the early diagnosis of type 2 diabetes mellitus and Alzheimer’s disease
27
Spogmay Yousafzai, Gul Zaman Khan, Sajad Ulhaq, Areebah, and Muhammad Rabbi Butt. "Improved Neural Network-Based System for Early and Accurate Diagnosis of Alzheimer Disease." Journal of Computer Science and Technology Studies 5, no. 4 (October 26, 2023): 32–40. http://dx.doi.org/10.32996/jcsts.2023.5.4.4.
Full textAbstract:
Alzheimer's disorder is a neurological condition that develops over time and mainly impacts cognitive processes like memory, thought, and behavior. It is one of the most typical reasons for dementia, a syndrome marked by a loss of cognitive ability that interferes with individual daily activities. Recent techniques for diagnosing Alzheimer's illness frequently combine positron emission tomography (PET) scans with magnetic resonance imaging (MRI), which can identify mutations in the brain caused by the illness, such as the buildup of beta-amyloid plaques and tau tangles. Furthermore, analysis of blood samples and cerebrospinal fluid is also a widely used method for the diagnosis of Alzheimer’s disease. Machine learning and deep learning-based techniques play a vital role in examining complex structures in brain images and other data, contributing to the timely and precise identification of Alzheimer's disease. Artificial intelligence-based techniques can help prompt detection and treatment, leading to more efficient care for Alzheimer's disease. This study uses convolutional neural networks (CNN) with MRI-based datasets for early and accurate diagnosis of Alzheimer’s disease. The proposed approach has shown excellent results in AD diagnosis.
28
Engelhardt, Eliasz, and Marleide da Mota Gomes. "Alzheimer's 100th anniversary of death and his contribution to a better understanding of Senile dementia." Arquivos de Neuro-Psiquiatria 73, no. 2 (February 2015): 159–62. http://dx.doi.org/10.1590/0004-282x20140207.
Full textAbstract:
Initially the trajectory of the historical forerunners and conceptions of senile dementia are briefly presented, being highlighted the name of Alois Alzheimer who provided clinical and neuropathological indicators to differentiate a group of patients with Senile dementia. Alzheimer's examination of Auguste D’s case, studied by him with Bielschowsky’s silver impregnation technique, permitted to identify a pathological marker, the intraneuronal neurofibrillary tangles, characterizing a new disease later named after him by Kraepelin – Alzheimer’s disease. Over the time this disorder became one of the most important degenerative dementing disease, reaching nowadays a status that may be considered as epidemic.
29
Hoxha, Donika, Biljana Bauer, Gjoshe Stefkov, and Gresa Hoxha. "Phenolic phytochemicals for treatment of Alzheimer’s condition - a review." 68 68, no. 02 (2022): 3–15. http://dx.doi.org/10.33320/maced.pharm.bull.2022.68.02.001.
Full textAbstract:
The progressive neurodegenerative disease, Alzheimer's disease, affects daily life due to severe memory loss and declining cognitive function. Alzheimer's disease has several hypotheses for its pathophysiology, and on the basis of those hypotheses, researchers are exploring a variety of pathologic targets to find a cure or symptomatic treatment. It has long been known that plants are effective in treating dementia, amnesia, and Alzheimer's disease. A lot of preclinical and clinical studies on plant-based drugs have shown promising results in treating the disease. In this review, we will focus on plants rich in phenolic phytochemicals and the benefit of those phytochemicals in Alzheimer’s disease treatment. Keywords: Alzheimer's disease, phenolic phytochemicals, neurodegenerative disease
30
Sree, M. Monika Bhargavi Sandhya. "Early detection of Alzheimer’s Disease using Deep Learning." INTERANTIONAL JOURNAL OF SCIENTIFIC RESEARCH IN ENGINEERING AND MANAGEMENT 08, no. 05 (May 22, 2024): 1–5. http://dx.doi.org/10.55041/ijsrem34463.
Full textAbstract:
alzheimer's Disease (AD) is a progressive neurodegenerative disorder that affects millions of people worldwide and causes cognitive impairment. It is the most common cause of dementia, a general term for a decline in cognitive abilities that interfere with daily life. Deep Learning, the subset of Artificial Intelligence is used in the early detection of Alzheimer's Disease. The human-level performance of the Deep Learning algorithm has been effectively shown in different disciplines. There isn’t a specific algorithm that is universal, but various Deep Learning algorithms, are used for the early detection of Alzheimer’s Disease. Researchers developed a blood test that could detect Alzheimer’s Disease promoting compounds in blood before the symptoms emerged. These findings may lead to early diagnostic tests for Alzheimer’s and other neurodegenerative diseases. Through research on the “Early detection of Alzheimer’s Disease using Deep Learning”, we can learn more about the potential of using advanced technology to identify the disease at its earliest stages. It also discusses the challenges and limitations of using Deep Learning for Alzheimer's Disease detection and highlights the need for future research in this area. Additionally, it can provide insights into the progression of the disease and potentially lead to the development of more accurate diagnostic tools. KEYWORDS: Alzheimer’s Disease, neurodegenerative, dementia, Early diagnosis, Deep Learning algorithms
31
Vitadella, Veronika, Catherine Putri Bulan, Julius Alvin Novensius Sinurat, Madyawati Latief, Yusnaidar Yusnaidar, and Indra Lasmana Tarigan. "Studi In Silico Senyawa Bioaktif Daun Miana (Coleus scutellariodes (L). Benth) sebagai Inhibitor Enzim Asetikolineterase (Ache) pada Alzheimer." Jurnal Sains dan Kesehatan 6, no. 2 (April 30, 2024): 282–91. http://dx.doi.org/10.25026/jsk.v6i2.2198.
Full textAbstract:
Abstract Alzheimer's contamination is a neurodegenerative sickness brought about by a decline in the blend of acetylcholine because of the breakdown of acetylcholine into choline and the determination of acidic corrosive by the compound Acetylcholinesterase (Hurt). Compounds known to have heartbeat restraining developments are promising medications for the treatment of these contaminations. In this investigation, in-silico studies were done on the blend found in Miana (Coleus) further to see whether this combination could be utilized as a remedial application in the treatment of Alzheimer's illness utilizing sub-nuclear docking procedures. From the consequences of the examination, it is realized that the Pyrazolopyridine compound is the best medication contender with a limiting energy and stable limitation benefit of - 6.96 kcal/mol and 7.95 µm separately, with hydrogen securities happening in the destructive development of amino SER 293. Keywords: Alzheimer’s; In Silico; Miana Abstrak Penyakit Alzheimer adalah infeksi neurodegenerative, dan terjadi karena menurunnya kombinasi asetilkolin dampak dari penguraian asetilkolin menjadi kolin dan derivasi asam asetat oleh senyawa Asetilkolinesterase (Hurt). Larutan yang diketahui memiliki gerakan penghambatan denyut merupakan obat yang menjanjikan untuk pengobatan infeksi ini. Dalam eksplorasi ini, studi in-silico dilakukan pada campuran yang ditemukan di Miana (Coleus) selanjutnya untuk melihat apakah campuran ini dapat digunakan sebagai aplikasi pengobatan dalam pengobatan penyakit Alzheimer dengan menggunakan strategi docking sub-atomik. Dari hasil penyelidikan diketahui bahwa senyawa Pyrazolopyridine adalah pesaing obat terbaik dengan energi ikatan dan keuntungan stabil pengekangan masing-masing - 6,96 kkal/mol dan 7,95 µm, dengan ikatan hidrogen terjadi pada penumpukan korosif amino SER 293. Kata Kunci: Alzheimer’s; In Silico; Miana
32
Malinchoc, M., W. A. Rocca, R. C. Colligan, K. P. Offord, and E. Kokmen. "Premorbid Personality Characteristics in Alzheimer’s Disease: An Exploratory Case–Control Study." Behavioural Neurology 10, no. 4 (1997): 117–20. http://dx.doi.org/10.1155/1997/362379.
Full textAbstract:
Linking data from a case–control study of Alzheimer’s disease with data from a Minnesota Multiphasic Personality Inventory (MMPI) outpatient study, we identified 13 Alzheimer's disease cases and 16 controls for case–control comparison. The mean time between personality testing and onset of Alzheimer's disease (or corresponding age for controls) was 13 years in cases and 14 years in controls. Alzheimer's disease cases, but not the controls, had scores significantly greater than the normative reference on MMPI scales measuring Social Introversion (p = 0.05), and Pessimism (p = 0.01). When compared to controls, Alzheimer's disease cases had significantly greater scores on the Social Introversion scale (p = 0.03). Despite the small sample size and some design limitations of this exploratory study, our findings may suggest that subjects who score higher on these personality scales have a greater risk of Alzheimer's disease.
33
Heckmann, Bradlee. "Beyond amyloid: What's next for Alzheimers disease therapeutics?" Open Access Government 38, no. 1 (April 13, 2023): 116–17. http://dx.doi.org/10.56367/oag-038-10770.
Full textAbstract:
Beyond amyloid: What's next for Alzheimers disease therapeutics? Bradlee Heckmann, PhD, from USF Health Neuroscience Institute, Byrd Alzheimer's Center & Asha Therapeutics, in this discussion goes beyond amyloid, asking what's next for Alzheimer's Disease therapeutics. The recent approvals of aducanumab and lecanamab, targeting amyloid beta, a key pathogenic hallmark of Alzheimer's Disease (AD), represent an impressive step forward in developing new treatment options for one of the most devastating neurological diseases. AD impacts over 5 million individuals in the United States and an estimated 20-24 million people globally. Moreover, AD represents the sixth leading cause of death and according to the Alzheimer's Association approximately one in three individuals will die with either AD or a related dementia.
34
Duduk, S. L., and E. G. Koroleva. "THE CASE OF THE SUPERVISION OF PATIENT SUFFERRING MIXED DEMENTIA WITH ALZHEIMER’S DISEASE." Health and Ecology Issues, no. 4 (December 28, 2009): 149–53. http://dx.doi.org/10.51523/2708-6011.2009-6-4-29.
Full textAbstract:
The article is presented the supervision of the authors of case mixed (atypical) dementia with Alzheimer's disease. The evaluation of patient is carried out with using modern functional, neurointrascopic and psychometric methods of diagnostics. This research detected as Alzheimer’s nature of disease, so and vascular disturbance, that lead to clinical picture of mixed dementia with Alzheimer's disease.
35
Reena, R., Srishti R, Harini M, Aezeden Mohamed, Ergasheva Surayyo, and Senthil Kumar R. "IoT-Based Assistant for Alzheimer's Patient with Reminder System and Tracking Using GPS." E3S Web of Conferences 399 (2023): 04053. http://dx.doi.org/10.1051/e3sconf/202339904053.
Full textAbstract:
In many nations, there is serious worry over the rising incidence of Alzheimer's disease (AD). New approaches are therefore needed for preventing, identifying, and helping people with AD. Alzheimer patients are facing difficulties during day-to-day activities in terms of traveling and receiving accurate information from their surroundings. We have proposed a smart belt that overcomes most of the problems of Alzheimer’s patients. The belt genuinely aids in identifying the challenges encountered in daily life. The smart belt is embedded with Arduino UNO and a global positioning system (GPS) that helps in sensing emergency alerts. The proposed smart belt provides continuous information about the location of Alzheimer’s patients to the concerned caretaker at an interval of five minutes. The pulse heart rate sensor installed on the belt monitors the health of the user. This heart rate sensor is used to detect the heart rate, and when the heart rate increases a buzzer makes an alert sound and sends an immediate message to the caretaker about the increased heart rate and location. It also contains a speaker module that tells the phone number and address of the caretaker and also some important help line emergency numbers. Sensors are used for achieving these functions. It supports them in remembering their family member’s numbers. This smart belt is useful for patients with mild and moderate Alzheimer's disease
36
Jiang, Zhiyi. "Purposed potential Alzheimer’s Disease treatment based on the results from current primary research models." Highlights in Science, Engineering and Technology 36 (March 21, 2023): 969–77. http://dx.doi.org/10.54097/hset.v36i.6139.
Full textAbstract:
Alzheimer’s Disease is one of the most known neurodegenerative diseases that causes over 100,000 deaths till now. The pathology of Alzheimer’s Disease is still not fully clear, but the most widely accepted pathology is the chronic endoplasmic reticulum (ER) stress caused by neurotoxicity via amyloid beta (Aß) plaques and intracellular tau tangles. In Alzheimer's patients, the abnormal Aß plaques and tau tangles cause oxidative stress and induce chronic ER stress, which can hardly be relieved by the normal UPR pathway. One potential treatment for rescuing the excessive ER stress caused by Aß accumulation in human neural cells is the Salubrinal (Sal) treatment. Amentoflavone (AF) treatment is a plausible treatment to alleviate cell death stress due to pyroptosis in Alzheimer's patients. Latrepirdine (LAT) is a treatment that can induce autophagy with the help of ATG5. Mitophagy is a special form of autophagy that degrades dysfunctional mitochondria and does not function well in Alzheimer's patients. Treatment like NMN, UA, and AC can effectively induce mitophagy, decrease memory loss, and relieve common Alzheimer’s pathology like Aß plaques and tau tangles. In this review, the primary research on four key mechanisms in Alzheimer's etiology - UPR pathway(apoptosis), pyroptosis, autophagy and mitophagy - will be discussed and some potential treatments targeting these four mechanisms will be briefly introduced with the primary research results.
37
Tulbă, Delia, Liviu Cozma, Bogdan Ovidiu Popescu, and Eugenia Irene Davidescu. "Dysautonomia in Alzheimer's Disease." Medicina 56, no. 7 (July 8, 2020): 337. http://dx.doi.org/10.3390/medicina56070337.
Full textAbstract:
Alzheimer's disease is the most common neurodegenerative disorder, and its prevalence increases with age. Although there is a large amount of scientific literature focusing on Alzheimer's disease cardinal cognitive features, autonomic nervous system dysfunction remains understudied despite being common in the elderly. In this article, we reviewed the evidence for autonomic nervous system involvement in Alzheimer's disease. We identified four major potential causes for dysautonomia in Alzheimer's disease, out of which two are well-studied (comorbidities and medication) and two are rather hypothetical (Alzheimer's pathology and brain co-pathology). Although there appears to be some evidence linking Alzheimer's disease pathology to autonomic nervous system dysfunction, there is an important gap between two types of studies; histopathologic studies do not address dysautonomia manifestations, whereas clinical studies do not employ histopathologic diagnostic confirmation. Moreover, brain co-pathology is emerging as an important confounding factor. Therefore, we consider the correlation between dysautonomia and Alzheimer's disease to be an open question that needs further study. Nevertheless, given its impact on morbidity and mortality, we emphasize the importance of assessing autonomic dysfunction in patients with Alzheimer clinical syndrome.
38
Lee, PhD, CTRS, Yongho, Carla E. S. Tabourne, PhD, and Jaesub Yoon, PhD. "Effects of life review program on emotional well-being of Korean elderly with Alzheimer’s disease." American Journal of Recreation Therapy 7, no. 2 (April 1, 2008): 35. http://dx.doi.org/10.5055/ajrt.2008.0014.
Full textAbstract:
Emotional well-being is an important aspect of health for individuals with Alzheimer's disease, and self-esteem, depression, and life satisfaction have been identified as factors that comprise emotional well-being. As individuals undergo physical and psychological change associated with aging process, they tend to review their lives to achieve a sense of well-being in an effort to compensate for loss due to aging process. It evidences in the literature that the life review program (LRP) is an effective therapeutic recreation intervention to increase emotional well-being of elders with Alzheimer’s disease. With 17 Korean elders with Alzheimer’s disease, the findings of the current study showed some significant effects on Korean elderly with Alzheimer's disease in their emotional well-being. Although long-term effects of the LRP were questionable, the LRP was effective to make a therapeutic change in emotional well-being of Korean elderly with Alzheimer's disease.
39
Patten, Ryan Van, Anne M. Fagan, and David A. S. Kaufman. "Differential Cued-Stroop Performance in Cognitively Asymptomatic Older Adults with Biomarker-Identified Risk for Alzheimer’s Disease: A Pilot Study." Current Alzheimer Research 15, no. 9 (July 11, 2018): 820–27. http://dx.doi.org/10.2174/1567205015666180404170359.
Full textAbstract:
Background: There exists a need for more sensitive measures capable of detecting subtle cognitive decline due to Alzheimer's disease. Objective: To advance the literature in Alzheimer’s disease by demonstrating that performance on a cued-Stroop task is impacted by preclinical Alzheimer's disease neuropathology. Method: Twenty-nine cognitively asymptomatic older adults completed a computerized, cued-Stroop task in which accuracy rates and intraindividual variability in reaction times were the outcomes of interest. Cerebrospinal fluid biomarkers of Aβ42 and tau were measured and participants were then grouped according to a published p-tau/Aβ42 cutoff reflecting risk for Alzheimer’s disease (preclinical Alzheimer's disease = 14; control = 15). Results: ANOVAs indicated that accuracy rates did not differ between the groups but 4-second delay incongruent color-naming Stroop coefficient of variation reaction times were higher in the preclinical Alzheimer’s disease group compared to the control group, reflecting increased within-person variability. Moreover, partial correlations showed no relationships between cerebrospinal fluid biomarkers and accuracy rates. However, increases in coefficient of variation reaction times correlated with decreased Aβ42 and increases in p-tau and the p-tau/Aβ42 ratio. Conclusion: Results supported the ability of the computerized, cued-Stroop task to detect subtle Alzheimer’s disease neuropathology using a small cohort of cognitively asymptomatic older adults. The ongoing measurement of cued-Stroop coefficient of variation reaction times has both scientific and clinical utility in preclinical Alzheimer’s disease.
40
Revathi, A., R. Kaladevi, Kadiyala Ramana, Rutvij H. Jhaveri, Madapuri Rudra Kumar, and M. Sankara Prasanna Kumar. "Early Detection of Cognitive Decline Using Machine Learning Algorithm and Cognitive Ability Test." Security and Communication Networks 2022 (January 20, 2022): 1–13. http://dx.doi.org/10.1155/2022/4190023.
Full textAbstract:
Elderly people are the assets of the country and the government can ensure their peaceful and healthier life. Life expectancy of individuals has expanded with technological advancements and survey tells that the elderly population will become double in the year 2030. The noninfectious cognitive dysfunction is the most important risk factor among elderly people due to a decline in their physiological function. Alzheimer, Vascular Dementia, and Dementia are the key reasons for cognitive inabilities. These diseases require manual assistance, which is difficult to provide in this fast-growing world. Prevention and early detection are the wise solution for the above diseases. Diabetes and hypertension are considered as main risk factors allied with Alzheimer's disease. Our proposed work applies a two-stage classification technique to improve prediction accuracy. In the first stage, we train a Support vector machine and a Random Forest algorithm to analyze the influence of diabetes and high blood pressure on cognitive decline. In the second stage, the cognitive function of the person with the possibility of Dementia is assessed using the neuropsychological test called Cognitive Ability Test (CAT). Multinomial Logistic Regression algorithm is applied to CAT results to predict the possibility of cognitive decline in their postlife. We classified the risk factor using the operational definitions: “No Alzheimer’s,” “Uncertain Alzheimer’s,” and “Definite Alzheimer’s”. SVM of stage 1 classifier predicts with an accuracy of 0.86 and Random Forest with an accuracy of 0.71. Multinomial Logistic algorithm of stage 2 classifier accuracy is 0.89. The proposed work enables early prediction of a person at risk of Alzheimer's Disease using clinical data.
41
Whitehouse, Peter J., Marian B. Patterson, Milton E. Strauss, David S. Geldmacher, James L. Mack, Grover C. Gilmore, and Elisabeth Koss. "Hallucinations." International Psychogeriatrics 8, S3 (May 1997): 387–92. http://dx.doi.org/10.1017/s1041610297003694.
Full textAbstract:
Studies conducted at our Alzheimer Center in Cleveland, Ohio, along with those of other investigators, have documented that visual hallucinations occur with sufficient frequency in Alzheimer's disease and related dementias to warrant further investigation of their meaning and implications. The largest data set in which frequency of hallucinations among persons with Alzheimer's disease has been examined comes from a collaboration among the National Institute of Aging Alzheimer's Disease Cooperative Study (ADCS), the Consortium to Establish a Registry for Alzheimer's Disease (CERAD), and the Case Western Reserve University Alzheimer's Disease Research Center (ADRC). As a part of this collaboration, we examined data from 556 patients with Alzheimer's disease treated at medical centers across the United States who had been rated using the CERAD Behavior Rating Scale for Dementia (BRSD). The BRSD is a comprehensive, informant-based tool that includes several questions concerning the frequency with which hallucinations and misperceptions were experienced during the month before the interview.
42
Kongjit, Chalermpon, and Prem Tuntisak. "Analysis and Design of Prototype Application of Caregivers’ Supportive System Phase 1 Alzheimer’s Based on a Design Thinking Process." International Journal of Online and Biomedical Engineering (iJOE) 17, no. 13 (December 6, 2021): 81–98. http://dx.doi.org/10.3991/ijoe.v17i13.24979.
Full textAbstract:
There are 7 million Alzheimer’s patients in Thailand, and 10% of people of 65 years of age or more are in the early stages of this pernicious disease. Alzheimer’s reduces the quality of daily life in several ways, as well as having a negative impact on the work performance of the patient’s family. Alzheimer's’ patients cannot receive proper care at home, despite the good intentions and efforts of family members, but this is the only option available to many families due to the cost of care in an external setting. The tendency for Alzheimer's patients to wander away from home and become lost is even more problematic for their families and this tendency is estimated to worsen as time goes by. Therefore, the purpose of this research is to alleviate the concern of families by preventing their loved ones who are suffering from Alzheimer's from wandering away from home and becoming lost by designing a prototype system that can track and monitor their movements.Design thinking was used in this research as a creative problem-solving approach to produce an application with the core functions of tracking and monitoring the movement of Alzheimer's patients. The application’s accuracy was validated by a scenario test, the results of which were discussed based on user feedback.
43
Cho, Eunhye, Youngran Yang, Hyun Kyung Kim, and Hye Young Kim. "Priorities of Family Caregivers in Preserving Functional Abilities of Individuals with Alzheimer's Disease Living at Home: A Best-Worst Scaling Approach." Research in Community and Public Health Nursing 35 (June 28, 2024): 156. http://dx.doi.org/10.12799/rcphn.2024.00556.
Full textAbstract:
Purpose: The decline in cognitive abilities among individuals with Alzheimer’s disease significantly impacts their Activities of Daily Living (ADLs), creating challenges and stress for their caregivers. This study aimed to investigate the priorities of family caregivers of community-dwelling individuals with Alzheimer's disease concerning the preservation of their loved ones' ADLs. Methods: We employed a cross-sectional design with a best-worst scaling approach (BWS), and developed a BWS questionnaire utilizing the 10 daily living items from the Disability Assessment for Alzheimer’s Disease scale. This questionnaire was administered to 132 caregivers of individuals with Alzheimer's disease. Data analysis was conducted using SPSS WIN 21.0 and the R statistical program. Results: The results revealed that "using the toilet without accidents" emerged as the top-ranked ADL that family caregivers preferred to preserve for the longest duration among individuals with Alzheimer's disease living at home. In contrast, "Managing money appropriately" was identified as a daily living activity considered relatively less critical to preserve. The study further indicated a preference among caregivers for preserving physical ADLs over instrumental ADLs. Conclusion: This research provides clinical evidence shedding light on the priorities of family caregivers in preserving the functional abilities of individuals with Alzheimer's disease within the community.
44
Hemangkorn, Nicha, Pamonphon Phummai, and Patranan Punyacharoen. "Effects of Essential Oils and Aromatic Plants on Alzheimer’s Disease and Dementia." International Journal of Science and Healthcare Research 6, no. 3 (September 3, 2021): 350–58. http://dx.doi.org/10.52403/ijshr.20210760.
Full textAbstract:
The primary objective of this research was to investigate how beneficial essential oils and aromatic plants are at curing Alzheimer’s disease and dementia. Alzheimer’s Disease (AD) is known to be one of the most incurable prevalent diseases in the elderly. Agitation, cognitive impairments, communication difficulty, irritability, and confusion may advance in AD patients. Even though the behavioral causes contributing to the disease have not yet been discovered, aggregation of tau and amyloid proteins is found in the brain of patients with Alzheimer’s. With numerous experiments conducted on these proteins, scientists have surmised that this accumulation is a causative factor of Alzheimer’s disease. Multiple scientists and experts have carried out several studies regarding the enlargement of amyloid plaques on Alzheimer’s. In addition, the effects of aromatherapy, including divergent results of alternative essential oils, have been analyzed. This paper examines the distinctions between Alzheimer's disease and dementia. The review elaborates on the causes and the symptoms before describing the effects of essential oils and aromatic plants. Subsequently, this provides rudiments regarding the benefits and hazards of applying essential oils and aromatic plants to treat either Alzheimer's disease or dementia. This study focuses on utilizing essential oils and aromatic plants in the medical profession as an alternative treatment for Alzheimer's disease and dementia. Likewise, a couple of case studies are shown in the paper with the analysis of amyloid plaques in mice and the effectiveness of lavender, rosemary, and orange essential oils on participants. Keywords: Alzheimer’s disease Dementia Essential oils Aromatic plants Aromatherapy Amyloid and Tau
45
Shim, Yong S., Catherine M. Roe, Virginia D. Buckles, and John C. Morris. "Clinicopathologic Study of Alzheimer's Disease: Alzheimer Mimics." Journal of Alzheimer's Disease 35, no. 4 (May 21, 2013): 799–811. http://dx.doi.org/10.3233/jad-121594.
Full text
46
Kalpana R. Adarkhi, Himanshu A. Patel, and Raksha K. Patel. "A Comprehensive Review of Advancement in Speech-Based Approach for Alzheimer Disease Detection in India." International Research Journal on Advanced Engineering and Management (IRJAEM) 2, no. 04 (April 16, 2024): 1039–47. http://dx.doi.org/10.47392/irjaem.2024.0138.
Full textAbstract:
Alzheimer’s Disease (AD), accounting for 60%-70% of dementia cases, is poised to afflict India as the second-largest country by mid-century, as indicated by a recent World Health Organization (WHO) study. The socio-economic landscape in India presents unique challenges, with a population that may not be adequately educated on allocating resources for healthcare beyond the age of 60, especially for conditions like Alzheimer's, which currently lacks a definitive cure. Addressing this impending health crisis necessitates innovative, early diagnosis and cost-effective solutions. This comprehensive review paper explores the potential of utilizing speech data analysis for the early detection of Alzheimer’s Disease (AD), offering a pragmatic approach to mitigate the severity of cases. By harnessing speech data, the aim is to diagnose the condition in its early stages, minimizing costs and enabling timely interventions to impede its progression. Early diagnosis is paramount, as it opens doors to effective treatments and preventative measures. The paper systematically reviews various processes involved in developing a mathematical model for the early detection of Alzheimer’s Disease (AD). It delves into key aspects such as data collection methodologies, pre-processing techniques, feature extraction methods, and diverse classifiers. The intention is to provide a thorough understanding of the intricacies involved in creating an accurate and reliable model for early Alzheimer's detection. In light of Alzheimer’s Disease (AD) representing a substantial majority of dementia cases, this review paper serves as a valuable resource for researchers, healthcare professionals, and policymakers. It fosters a deeper comprehension of potential avenues for leveraging speech data specifically in the context of Alzheimer's. As we confront the impending surge in Alzheimer's cases in India, this comprehensive review work contributes to the foundation of knowledge needed to develop scalable and accessible solutions, making a substantial impact on public health.
47
Nurbaiti, Nurbaiti, Shinta Gunawati Sutoro, Eny Supriyaningsih, Sri Wiwik Wiyanti, and Imas Maesaroh. "Edukasi untuk Deteksi Dini dan Perawatan Lansia dengan Alzheimer di Masa Pandemi Covid-19." Jurnal Kreativitas Pengabdian Kepada Masyarakat (PKM) 6, no. 7 (June 25, 2023): 2887–95. http://dx.doi.org/10.33024/jkpm.v6i7.10093.
Full textAbstract:
ABSTRAK Poltekkes Kemenkes Jakarta II melaksanakan kegiatan edukasi kesehatan lansia. Penduduk usia lanjut dengan kondisi demensia Alzheimer membutuhkan perhatian khusus. Jumlah penduduk lansia di Indonesia yang kian bertambah menjadi tantangan bagi keluarga-keluarga Indonesia. Kegiatan edukasi dilakukan secara online dalam bentuk workshop untuk memperkenalkan kasus demensia Alzheimer, cara merawat pasiennya dan mendeteksi gejala-gejalanya. Peserta adalah warga kompleks Depsos, para mahasiswa dan masyarakat umum. Tujuan kegiatan ini untuk meningkatkan pengetahuan dan keterampilan peserta mendeteksi dan merawat lansia dengan demensia Alzheimer. Kegiatan dilaksanakan secara online dengan bantuan materi ajar yang dikemas dalam bentuk e-booklet dan video pembelajaran. Kegiatan dilengkapi dengan diskusi dan praktek bersama menggunakan instrumen Clockwise dan senam untuk mencegah penyakit Alzheimer. Kegiatan edukasi terselenggara dengan baik pada saat kondisi pandemi Covid-19. Kata Kunci: Edukasi, Demensia Alzheimer, Clockwise ABSTRACT Poltekkes Poltekkes Kemenkes Jakarta II carried out health education activities for the elderly. Elderly population with Alzheimer's dementia condition requires special attention. The increasing number of elderly people in Indonesia is a challenge for Indonesian families. Educational activities were carried out online in the form of workshops to introduce Alzheimer's dementia cases, how to treat patients and detect their symptoms. The participants were residents of the Ministry of Social Affairs complex, students and the general public. The purpose of this activity was to increase participants' knowledge and skills in detecting and caring for elderly people with Alzheimer's dementia. Activities carried out online were equipped with teaching materials in the form of e-booklets and learning videos. in this activity there were discussions, practice using Clockwise instruments and gymnastics to prevent Alzheimer's disease. Educational activities were well organized during the Covid-19 pandemic. Keywords: Education, Demensia Alzheimer, Clockwise
48
Vyshnavi Ramineni, Vyshnavi Ramineni, and Goo-Rak Kwon Goo-Rak Kwon. "An Implementation of Effective CNN Model for AD Detection." Korean Institute of Smart Media 13, no. 6 (June 28, 2024): 90–97. http://dx.doi.org/10.30693/smj.2024.13.6.90.
Full textAbstract:
This paper focuses on detecting Alzheimer’s Disease (AD). The most usual form of dementia is Alzheimer's disease, which causes permanent cause memory cell damage. Alzheimer's disease, a neurodegenerative disease, increases slowly over time. For this matter, early detection of Alzheimer's disease is important. The purpose of this work is using Magnetic Resonance Imaging (MRI) to diagnose AD. A Convolution Neural Network (CNN) model, Reset, and VGG the pre-trained learning models are used. Performing analysis and validation of layers affects the effectiveness of the model. T1-weighted MRI images are taken for preprocessing from ADNI. The Dataset images are taken from the Alzheimer's Disease Neuroimaging Initiative (ADNI). 3D MRI scans into 2D image slices shows the optimization method in the training process while achieving 96% and 94% accuracy in VGG 16 and ResNet 18 respectively. This study aims to classify AD from brain 3D MRI images and obtain better results.
49
Akkaş, Hülya, Fatma Latifoğlu, and Mahmut Tokmakçı. "The Diagnosis of Alzheimer's Disease using EEG Signals." European Journal of Research and Development 3, no. 3 (October 31, 2023): 1–13. http://dx.doi.org/10.56038/ejrnd.v3i3.273.
Full textAbstract:
Alzheimer is a common and significant neurological disorder worldwide, typically associated with age-related dementia. Alzheimer's patients exhibit slower brain activities compared to healthy individuals, and the most prominent symptom of the disease is the impairment of cognitive functions. Early diagnosis of Alzheimer's is crucial to prevent the rapid progression of the disease. In this study, the feasibility of using electroencephalography (EEG) signals, a non-invasive, cost-effective, and objective method, to facilitate the diagnosis of Alzheimer's Disease (AD) was investigated.
The study utilized EEG signals from both Alzheimer's patients and healthy individuals, which were made publicly available by Florida State University. Preprocessing was applied to the EEG signals to eliminate existing noise. Subsequently, a total of 34 various features in the time and frequency domains, such as entropy, Hjorth parameters, etc., were extracted from the EEG signals for the purpose of Alzheimer's diagnosis. Machine learning techniques, including decision trees (DT), support vector machines (SVM), and artificial neural networks (ANN), were applied to classify the data, and success rates for Alzheimer's detection were achieved.
50
Harshitha, Gowthami Chamarajan, and Charishma Y. "Alzheimer's Disease: A Survey." International Journal of Artificial Intelligence 8, no. 1 (June 22, 2021): 33–39. http://dx.doi.org/10.36079/lamintang.ijai-0801.220.
Full textAbstract:
Alzheimer's Diseases (AD) is one of the type of dementia. This is one of the harmful disease which can lead to death and yet there is no treatment. There is no current technique which is 100% accurate for the treatment of this disease. In recent years, Neuroimaging combined with machine learning techniques have been used for detection of Alzheimer's disease. Based on our survey we came across many methods like Convolution Neural Network (CNN) where in each brain area is been split into small three dimensional patches which acts as input samples for CNN. The other method used was Deep Neural Networks (DNN) where the brain MRI images are segmented to extract the brain chambers and then features are extracted from the segmented area. There are many such methods which can be used for detection of Alzheimer’s Disease.